Capital Investment Services of America Inc. boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 7.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,147 shares of the life sciences company’s stock after purchasing an additional 3,386 shares during the period. Capital Investment Services of America Inc.’s holdings in Illumina were worth $9,027,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. HighMark Wealth Management LLC acquired a new stake in shares of Illumina during the first quarter worth approximately $33,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Illumina during the first quarter worth approximately $33,000. Clearstead Trust LLC increased its holdings in shares of Illumina by 125.7% during the first quarter. Clearstead Trust LLC now owns 158 shares of the life sciences company’s stock worth $37,000 after buying an additional 88 shares in the last quarter. BOKF NA acquired a new stake in shares of Illumina during the first quarter worth approximately $38,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Illumina by 64.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 194 shares of the life sciences company’s stock worth $39,000 after buying an additional 76 shares in the last quarter. Institutional investors own 92.17% of the company’s stock.
In other Illumina news, SVP Susan H. Tousi sold 500 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $200.00, for a total value of $100,000.00. Following the transaction, the senior vice president now directly owns 46,522 shares of the company’s stock, valued at approximately $9,304,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 1,500 shares of company stock valued at $278,560. 0.13% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Illumina Stock Down 2.9 %
Shares of Illumina stock traded down $4.34 during trading hours on Friday, reaching $146.15. 3,543,451 shares of the company’s stock were exchanged, compared to its average volume of 1,414,951. The company has a 50 day moving average of $174.51 and a two-hundred day moving average of $197.06. Illumina, Inc. has a fifty-two week low of $145.14 and a fifty-two week high of $248.87. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.23. The stock has a market cap of $23.14 billion, a P/E ratio of -5.49, a P/E/G ratio of 8.15 and a beta of 1.12.
Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The life sciences company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.30. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. Illumina had a negative net margin of 93.86% and a positive return on equity of 1.97%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.57 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 0.83 EPS for the current fiscal year.
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- Five stocks we like better than Illumina
- EV Stocks and How to Profit from Them
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Stock Dividend Cuts Happen Are You Ready?
- MarketBeat Week in Review – 9/11 – 9/15
- Space Investment: How to Invest in Space Exploration
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.